Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A long-term clinical experience with Lonidamine.

T Battelli, P Manocchi, L Giustini

    Oncology
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Investigating the relationship between autistic traits and symptoms and Catatonia Spectrum.

    European psychiatry : the journal of the Association of European Psychiatrists·2022
    Same author

    Morphological and karyological studies on in vitro Sertoli cells of adult crab-eating macaques (Macaca fascicularis).

    American journal of primatology·2020
    Same author

    Systemic injection of an H4 receptor agonist induces a decrease in CREB and pCREB levels in the cerebellar vermis and prefrontal cortex in mice.

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2019
    Same author

    Intra-vermis H4 receptor agonist impairs performance in anxiety- and fear-mediated models.

    Brain research bulletin·2017
    Same author

    Cholinergic agonist reverses H1-induced memory deficit in mice.

    Progress in neuro-psychopharmacology & biological psychiatry·2016
    Same author

    Intra-amygdala microinjections of chlorpheniramine impair memory formation or memory retrieval in anxiety- and fear-mediated models.

    Brain research bulletin·2016

    Lonidamine (LNA) shows promise as a cancer treatment with fewer side effects than traditional chemotherapy. It demonstrated efficacy alone and enhanced other agents, particularly for advanced lung and brain tumors.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Lonidamine (LNA) is an investigational chemotherapeutic agent.
    • LNA has been evaluated in advanced-stage cancers, both as monotherapy and in combination regimens.
    • Standard chemotherapeutics often present significant toxicities.

    Purpose of the Study:

    • To assess the efficacy and safety profile of Lonidamine (LNA) in cancer treatment.
    • To evaluate LNA's effectiveness as a standalone agent and its synergistic potential with other chemotherapeutic drugs.

    Main Methods:

    • Clinical investigation of Lonidamine (LNA) in patients with advanced-stage tumors.
    • Evaluation of both acute and long-term treatment outcomes.
    • Comparative analysis of LNA's side effect profile against conventional chemotherapy.

    Related Experiment Videos

    Main Results:

    • Lonidamine (LNA) exhibited a distinct side effect profile, including myalgia, photosensitivity, and auditory changes, differing from typical chemotherapy adverse events.
    • Monotherapy with LNA resulted in partial remission in one ovarian adenocarcinoma case and disease stabilization in two breast carcinoma and one microcytoma cases.
    • Combination therapy demonstrated potentiated effects of chemotherapeutic agents, especially in treating brain metastases and lung adenocarcinomas.

    Conclusions:

    • Lonidamine (LNA) presents a favorable safety profile compared to conventional chemotherapeutic agents.
    • LNA shows potential as an effective agent in specific advanced-stage cancers and as a potentiator of existing chemotherapies, particularly for challenging tumor types like brain metastases and lung adenocarcinomas.